Literature DB >> 26378641

Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander.

Ester Vanni1, Andrea Marengo1, Lavinia Mezzabotta1, Elisabetta Bugianesi1.   

Abstract

The top three leading causes of death in patients with nonalcoholic fatty liver disease (NAFLD) in descending order are cardiovascular disease, cancer, and liver disease. It is clear now that the increased risk of metabolic and macro- and microvascular complications in NAFLD stems from the associated features of metabolic syndrome. However, NAFLD itself may contribute to the spectrum of risk factors associated with insulin resistance. The primary focus of this review is to summarize the main systemic associations of NAFLD, as well as to discuss the mechanisms that link them to NAFLD. Hepatic lipid accumulation in NAFLD impairs hepatic glucose and lipid metabolism further increasing the risk of type 2 diabetes mellitus and of cardiovascular disease, independently of established risk factors. The incidence, prevalence, and severity of these complications are proportional to the histological severity of liver damage suggesting that NAFLD, but particularly nonalcoholic steatohepatitis, can also contribute to the low-grade inflammatory state through the systemic release of several markers of inflammation, oxidative stress, and of procoagulant factors. The clinical implication of these findings is that patients with NAFLD require a multidisciplinary evaluation, with a major focus on type 2 diabetes mellitus and cardiovascular disease complications and may benefit from more intensive surveillance and early treatment interventions to decrease the risk for cardiovascular and kidney complications. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2015        PMID: 26378641     DOI: 10.1055/s-0035-1562944

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  27 in total

Review 1.  Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflame.

Authors:  Samar H Ibrahim; Petra Hirsova; Harmeet Malhi; Gregory J Gores
Journal:  Dig Dis Sci       Date:  2015-12-01       Impact factor: 3.199

Review 2.  Does Nonalcoholic Fatty Liver Disease Increase the Risk for Extrahepatic Malignancies?

Authors:  Somaya Albhaisi; Arun J Sanyal
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-04-13

3.  Low Birthweight Increases the Likelihood of Severe Steatosis in Pediatric Non-Alcoholic Fatty Liver Disease.

Authors:  Elisabetta Bugianesi; Carla Bizzarri; Chiara Rosso; Antonella Mosca; Nadia Panera; Silvio Veraldi; Andrea Dotta; Germana Giannone; Massimiliano Raponi; Marco Cappa; Anna Alisi; Valerio Nobili
Journal:  Am J Gastroenterol       Date:  2017-05-30       Impact factor: 10.864

Review 4.  Nonalcoholic Fatty Liver Disease: Lipids and Insulin Resistance.

Authors:  Paul D Berk; Elizabeth C Verna
Journal:  Clin Liver Dis       Date:  2016-02-18       Impact factor: 6.126

Review 5.  Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?

Authors:  Agostino Di Ciaula; Salvatore Passarella; Harshitha Shanmugam; Marica Noviello; Leonilde Bonfrate; David Q-H Wang; Piero Portincasa
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

Review 6.  Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD).

Authors:  Ignazio Grattagliano; Agostino Di Ciaula; Jacek Baj; Emilio Molina-Molina; Harshitha Shanmugam; Gabriella Garruti; David Q-H Wang; Piero Portincasa
Journal:  Methods Mol Biol       Date:  2021

7.  New Approach to Drug Discovery of a Safe Mitochondrial Uncoupler: OPC-163493.

Authors:  Takashi Okamoto; Takahiro Shimada; Chiharu Matsumura; Hitomi Minoshima; Takashi Ban; Motohiro Itotani; Toshio Shinohara; Shigekazu Fujita; Satoshi Matsuda; Seiji Sato; Naohide Kanemoto
Journal:  ACS Omega       Date:  2021-06-21

8.  Propensity for Intra-abdominal and Hepatic Adiposity Varies Among Ethnic Groups.

Authors:  Unhee Lim; Kristine R Monroe; Steve Buchthal; Bo Fan; Iona Cheng; Bruce S Kristal; Johanna W Lampe; Meredith A Hullar; Adrian A Franke; Daniel O Stram; Lynne R Wilkens; John Shepherd; Thomas Ernst; Loïc Le Marchand
Journal:  Gastroenterology       Date:  2018-11-13       Impact factor: 33.883

Review 9.  Non-Alcoholic Fatty Liver Disease and Extra-Hepatic Cancers.

Authors:  Claudia Sanna; Chiara Rosso; Milena Marietti; Elisabetta Bugianesi
Journal:  Int J Mol Sci       Date:  2016-05-12       Impact factor: 5.923

10.  A nomogram for predicting metabolic steatohepatitis: The combination of NAMPT, RALGDS, GADD45B, FOSL2, RTP3, and RASD1.

Authors:  Shenling Liao; He He; Yuping Zeng; Lidan Yang; Zhi Liu; Zhenmei An; Mei Zhang
Journal:  Open Med (Wars)       Date:  2021-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.